Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ProKidney Corp. Class A Ordinary Shares

PROK

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Last trade $1.09
Day change +$0.045 (+4.33%)
Day range $1.04 – $1.11
Volume 663,743
Market cap $217M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$217.33M
Price / earnings
—
Price / book
-0.24×
Price / sales
280.43×
EV / sales
175.46×
EV / EBITDA
-0.73×

Profitability

Earnings per share
-$0.49
Return on assets
-49.12%
Return on equity
11.39%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
5.04×
Quick ratio
5.04×
Cash ratio
2.71×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$167.83M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PROK, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$174K$150K$226K$225K$217K$221K$230K$76K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$174K$150K$226K$225K$217K$221K$230K$76K
Selling, general and administrative$13.09M$12.43M$11.32M$11.44M$11.94M$14.05M$14.36M$11.87M
Research and development$40.85M$36.1M$33.84M$34.16M$26.82M$25.88M$27.26M$39.78M
Total operating expenses$53.93M$48.52M$45.16M$45.6M$38.76M$39.93M$41.62M$51.65M
Operating income-$53.76M-$48.37M-$44.93M-$45.37M-$38.54M-$39.71M-$41.39M-$51.57M
Interest expense-$1K-$1K-$15K-$1K-$2K-$1K$0-$2K
Income before taxes-$52.23M-$46.44M-$42.62M-$42.44M-$35.28M-$36.12M-$37.36M-$46.78M
Income taxes-$436K$0$0-$1.59M$560K$848K$591K$1.7M
Net income-$51.79M-$46.44M-$42.62M-$40.85M-$35.84M-$36.97M-$37.95M-$48.48M
Net income attributable to common shareholders-$35.59M-$28.42M-$20.04M-$19.23M-$16.47M-$16.55M-$16.73M-$21.28M
EBITDA-$52.09M-$46.7M-$43.28M-$43.53M-$36.87M-$38.24M-$39.79M-$50M
Basic earnings per share-$0.17-$0.15-$0.14-$0.13-$0.12-$0.13-$0.13-$0.17
Diluted earnings per share-$0.17-$0.15-$0.14-$0.13-$0.12-$0.13-$0.13-$0.17

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

ProKidney Corp. (PROK) Reports Q3 Loss, Misses Revenue Estimates

ProKidney Corp. (PROK) reported a quarterly loss of $0.17 per share, missing consensus estimates of $0.13 by 30.77%. Revenue of $0.17 million also fell short of expectations by 13%. The stock has declined 49.6% year-to-date, significantly underperforming the S&P 500's 11.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

Merck KGaA (MKKGY) Lags Q3 Earnings Estimates

Merck KGaA reported quarterly earnings of $0.24 per share, missing consensus estimates of $0.50 by 52%, though revenues of $6.48 billion exceeded expectations by 5.32%. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. ProKidney Corp. is also mentioned as an upcoming earnings reporter in the same Medical-Drugs industry.

GlobeNewswire Inc.

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

ProKidney announced that eight abstracts, including one oral presentation, will be presented at ASN's Kidney Week 2026 in Denver. The abstracts present translational research and a pooled Phase 2 analysis supporting rilparencel's multifactorial mechanism of action for treating chronic kidney disease with type 2 diabetes, demonstrating kidney function stabilization and a strong safety profile.

GlobeNewswire Inc.

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

ProKidney reported full-year 2025 financial results with $270.0 million in cash and cash equivalents, supporting operations into mid-2027. The company achieved significant milestones including FDA alignment on an accelerated approval pathway for rilparencel using eGFR slope as a surrogate endpoint, positive Phase 2 REGEN-007 results, and strong enrollment momentum in the Phase 3 PROACT 1 study. The company expects to complete enrollment for the accelerated approval analysis by mid-2026 and deliver pivotal topline results in Q2 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.